YumanityLogo.jpg
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  
January 19, 2022 07:30 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
January 11, 2022 08:00 ET | Yumanity Therapeutics Inc
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation awards grant to accelerate early proof-of-concept...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2022 16:05 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 08:00 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021 18:00 ET | Yumanity Therapeutics Inc
BOSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics to Present at Multiple Upcoming November Investor Conferences
November 16, 2021 16:30 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 15, 2021 07:30 ET | Yumanity Therapeutics Inc
Announced Successful Phase 1b trial for YTX-7739 in Parkinson’s disease patients; YTX-7739 was well tolerated and demonstrated target engagement and favorable PK/PD and safety profiles Company...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2021 16:05 ET | Yumanity Therapeutics Inc
BOSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson’s Disease; Company Plans to Advance Program to Phase 2
November 10, 2021 07:00 ET | Yumanity Therapeutics Inc
YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...